B. Metzler seel. Sohn & Co. AG Buys 8,622 Shares of Revolution Medicines, Inc. $RVMD

Key Points

• B. Metzler seel. Sohn & Co. AG increased its stake in Revolution Medicines, Inc. by 50.1%, now holding 25,821 shares valued at approximately $913,000.
• Institutional investors control roughly 94.34% of Revolution Medicines' stock, indicating strong institutional interest and support.
• The company's stock has seen a high of $62.40 and a low of $29.17 within the last year, with current trading around $37.97 as of the latest report.

B. Metzler seel. Sohn & Co. AG raised its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 50.1% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 25,821 shares of the company's stock after acquiring an additional 8,622 shares during the quarter. B. Metzler seel. Sohn & Co. AG's holdings in Revolution Medicines were worth $913,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Farallon Capital Management LLC grew its position in shares of Revolution Medicines by 17.1% in the 4th quarter. Farallon Capital Management LLC now owns 13,248,692 shares of the company's stock valued at $579,498,000 after acquiring an additional 1,931,000 shares during the period. Wellington Management Group LLP raised its stake in Revolution Medicines by 8.9% in the 1st quarter. Wellington Management Group LLP now owns 11,787,921 shares of the company's stock worth $416,821,000 after purchasing an additional 966,230 shares in the last quarter. Janus Henderson Group PLC increased its holdings in shares of Revolution Medicines by 54.5% during the fourth quarter. Janus Henderson Group PLC now owns 9,483,999 shares of the company's stock worth $414,777,000 after purchasing an additional 3,346,755 shares during the period. Baker BROS. Advisors LP raised its position in shares of Revolution Medicines by 4.9% in the fourth quarter. Baker BROS. Advisors LP now owns 7,936,972 shares of the company's stock valued at $347,163,000 after buying an additional 367,882 shares in the last quarter. Finally, Nextech Invest Ltd. boosted its stake in shares of Revolution Medicines by 20.7% in the fourth quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company's stock valued at $332,472,000 after buying an additional 1,304,347 shares during the period. 94.34% of the stock is owned by institutional investors and hedge funds.

Revolution Medicines Price Performance

Shares of RVMD traded up $0.24 during trading hours on Wednesday, reaching $39.77. The stock had a trading volume of 1,794,176 shares, compared to its average volume of 1,873,605. The company has a debt-to-equity ratio of 0.13, a quick ratio of 11.79 and a current ratio of 11.79. Revolution Medicines, Inc. has a 12 month low of $29.17 and a 12 month high of $62.40. The stock has a market capitalization of $7.43 billion, a PE ratio of -8.84 and a beta of 1.12. The company's 50-day moving average is $37.20 and its two-hundred day moving average is $38.15.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.37). The business's revenue was up .0% on a year-over-year basis. During the same period last year, the business earned ($0.81) earnings per share. Research analysts expect that Revolution Medicines, Inc. will post -3.49 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Wedbush reaffirmed an "outperform" rating and issued a $73.00 price objective (up from $67.00) on shares of Revolution Medicines in a report on Tuesday, June 24th. Lifesci Capital initiated coverage on Revolution Medicines in a research note on Monday, August 18th. They issued an "outperform" rating and a $80.00 price target for the company. Needham & Company LLC reduced their price objective on shares of Revolution Medicines from $57.00 to $56.00 and set a "buy" rating on the stock in a research note on Thursday, August 7th. Wells Fargo & Company started coverage on shares of Revolution Medicines in a research report on Friday, August 15th. They issued an "overweight" rating and a $67.00 target price for the company. Finally, Oppenheimer upped their price target on shares of Revolution Medicines from $70.00 to $75.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Thirteen analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $69.92.

Revolution Medicines Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.